Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

Journal of the National Cancer Institute

Volumn 90, Issue 19, 1998, Pages 1473-1479

  Cairncross, J Gregory ^a   Ueki, Keisuke ^b   Zlatescu, Magdelena C ^a   Lisle, David K ^b   Finkelstein, Dianne M ^c   Hammond, Robert R ^d   Silver, Jonathan S ^b   Stark, Paul C ^c   Macdonald, David R ^a   Ino, Yasushi ^b   Ramsay, David A ^d   Louis, David N ^b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DELETION; GENE ISOLATION; HUMAN; HUMAN TISSUE; MALE; OLIGODENDROGLIOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 0032494479     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.19.1473     Document Type: Article

References (33)

1. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23: 360-4.
2. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573-4.
3. Cairncross JG, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:2013-21.
4. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992;76:741-5.
5. Kim L, Hochberg FH, Thornton AF, Harsh GR 4th, Patel H, Finkelstein D, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996;85:602-7.
6. Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 1995;11:412-5.
7. Louis DN, Cavenee WK. Molecular biology of central nervous system tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997. p. 2013-22.
8. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992;52:4277-9.
9. Kraus JA, Koopman J, Kaskel P, Maintz D, Brandner S, Louis DN, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-5.
10. Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW, et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996;13:2483-5.
11. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90.
12. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations m nonastrocytic human brain tumors. Cancer Res 1991;51:6202-5.
13. Maintz D, Fiedler K, Koopmann J, Rollbroker B. Nechev S. Lenartz D, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56: 1098-104.
14. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in coloreclal cancer. N Engl J Med 1994;331:213-21.
15. Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30.
16. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
17. Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994; 12:1886-9.
18. Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988;38:724-6.
19. Kleihues P, Burger PC, Scheithauer BW. Hislological typing of tumours of the central nervous system. Berlin: Springer-Verlag; 1993.
20. Louis DN, von Deimling A, Seizinger BR. A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. Am J Pathol 1992;141:777-82.
21. Louis DN, Rubio MP, Correa KM, Gusella JF, von Deimling A. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 1993;52: 507-15.
22. Rubio MP, Correa KM, Ueki K, Mohren Weiser HW, Gusella JF, von Deimling A, et al. The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res 1994;54:4760-3.
23. Bello MJ, Vaquero J, deCampos JM, Kusak ME, Sarasa JL, Saez-Castresana J, et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 1994;57:172-5.
24. Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 1993;52:31-8.
25. Rubio MP, von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993;53:3465-7.
26. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, et al. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 1996;55: 1026-31.
27. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol (Berl) 1991;81:675-9.
28. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998;57: 122-30.
29. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994; 53:11-21.
30. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305: 779-84.
31. Cairncross JG, Swinnen L, Stiff P, Rosenfeld S, Vaughan W, Paleologos N, et al. High-dose thiotepa with hematopoietic reconstitution (deferring radiation) for newly diagnosed aggressive oligodendroglioma. Proc ASCO 1997;16: 388.
32. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996;46:203-7.
33. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why? J Clin Oncol 1997;15:3423-6.